DE69233379D1 - Antivirus Wirkung und Auflösung von 2-Hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane - Google Patents

Antivirus Wirkung und Auflösung von 2-Hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane

Info

Publication number
DE69233379D1
DE69233379D1 DE69233379T DE69233379T DE69233379D1 DE 69233379 D1 DE69233379 D1 DE 69233379D1 DE 69233379 T DE69233379 T DE 69233379T DE 69233379 T DE69233379 T DE 69233379T DE 69233379 D1 DE69233379 D1 DE 69233379D1
Authority
DE
Germany
Prior art keywords
oxathiolane
hydroxymethyl
fluorocytosin
dissolution
antivirus activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233379T
Other languages
English (en)
Other versions
DE69233379T2 (de
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeg Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35276919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233379(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/659,760 external-priority patent/US5210085A/en
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of DE69233379D1 publication Critical patent/DE69233379D1/de
Publication of DE69233379T2 publication Critical patent/DE69233379T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69233379T 1991-02-22 1992-02-20 Antivirale Wirkung und Trennung von 2-Hydroxymethyl-5(5-Fluorocytosin-1-yl)-1,3-oxathiolan Expired - Lifetime DE69233379T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US07/659,760 US5210085A (en) 1990-02-01 1991-02-22 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US659760 1991-02-22
US73608991A 1991-07-26 1991-07-26
US736089 1991-07-26
US83115392A 1992-02-12 1992-02-12
US831153 1992-02-12

Publications (2)

Publication Number Publication Date
DE69233379D1 true DE69233379D1 (de) 2004-08-05
DE69233379T2 DE69233379T2 (de) 2005-07-14

Family

ID=35276919

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69233379T Expired - Lifetime DE69233379T2 (de) 1991-02-22 1992-02-20 Antivirale Wirkung und Trennung von 2-Hydroxymethyl-5(5-Fluorocytosin-1-yl)-1,3-oxathiolan
DE69233786T Expired - Lifetime DE69233786D1 (de) 1991-02-22 1992-02-20 Antivirale Wirkung und Auflösung von 2-Hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolanen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69233786T Expired - Lifetime DE69233786D1 (de) 1991-02-22 1992-02-20 Antivirale Wirkung und Auflösung von 2-Hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolanen

Country Status (25)

Country Link
EP (3) EP1439177B1 (de)
JP (2) JP2901160B2 (de)
KR (1) KR0172590B1 (de)
CN (4) CN1037682C (de)
AT (2) ATE469147T1 (de)
AU (2) AU679649B2 (de)
BG (1) BG62053B1 (de)
BR (1) BR9205661A (de)
CA (2) CA2513440C (de)
CZ (1) CZ295074B6 (de)
DE (2) DE69233379T2 (de)
DK (2) DK1439177T3 (de)
ES (2) ES2345102T3 (de)
FI (2) FI114915B (de)
HK (1) HK1026419A1 (de)
HU (2) HU227823B1 (de)
IE (1) IE920545A1 (de)
IL (1) IL100965A (de)
MX (1) MX9200747A (de)
MY (1) MY114350A (de)
NO (3) NO312399B1 (de)
NZ (2) NZ250842A (de)
PT (1) PT100151B (de)
RO (2) RO119365B1 (de)
WO (1) WO1992014743A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
HU226137B1 (en) * 1989-02-08 2008-05-28 Shire Canada Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
AU662130B2 (en) * 1991-03-06 1995-08-24 Emory University Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2171550C (en) 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ES2276404T3 (es) * 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
ID19490A (id) 1996-06-25 1998-07-16 Glaxo Group Ltd Kombinasi-kombinasi antiviral
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
WO1998041522A1 (en) 1997-03-19 1998-09-24 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
IT1290447B1 (it) 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
AU6898498A (en) 1997-04-07 1998-10-30 Triangle Pharmaceuticals, Inc. Use of mkc-442 in combination with other antiviral agents
JP2002500881A (ja) 1998-01-26 2002-01-15 フアーム−エコ・ラボラトリーズ・インコーポレーテツド 鏡像異性体分離のための酵素活性化担体
EA008609B1 (ru) 1998-02-25 2007-06-29 Эмори Юниверсити 2'-фторнуклеозиды
ES2232169T3 (es) 1998-08-12 2005-05-16 Gilead Sciences, Inc. Procedimiento de fabricacion de nucleosidos de 1,3-oxatiolano.
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
ATE254126T1 (de) 1998-12-23 2003-11-15 Shire Biochem Inc Antivirale nukleosidanaloga
KR100339786B1 (ko) * 1999-04-02 2002-06-07 안용현 라세미 혼합물 상태로 존재하는 뉴클레오시드로부터 거울상 이성질체의 분리 방법
EP1600451A3 (de) 1999-11-12 2008-09-10 Pharmasset, Inc. Herstellung von 2'-Deoxy-L-Nukleoside
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
US6828119B2 (en) * 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
DE10104231A1 (de) 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
CA2788498C (en) * 2001-03-01 2016-02-16 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
KR20050005442A (ko) 2002-04-12 2005-01-13 아칠리온 파르마세우티칼스 인코포레이티드 β-Ｌ-플루오로-2',3'-디데히드로사이티딘(β-Ｌ-ＦＤ4Ｃ)의합성 방법
JP4501135B2 (ja) * 2002-11-18 2010-07-14 シェア カナダ インコーポレーテッド ジオキソランヌクレオシド類似体の立体選択的製造方法
DE602004014470D1 (de) 2003-01-14 2008-07-31 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
WO2006096954A1 (en) * 2005-03-14 2006-09-21 Shire Biochem Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1´-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
PT2159224E (pt) 2007-06-18 2012-10-24 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
US8350030B2 (en) 2007-12-07 2013-01-08 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2R, 5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
JPWO2009107692A1 (ja) * 2008-02-29 2011-07-07 株式会社カネカ ２’−水酸基が保護されたリボヌクレオシド誘導体およびその製造方法
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP2376514A2 (de) 2008-12-23 2011-10-19 Pharmasset, Inc. Nukleosidanaloga
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
EP2377862A1 (de) 2010-03-29 2011-10-19 Esteve Química, S.A. Verfahren zur Gewinnung von Emtricitabin
AU2011235112B2 (en) 2010-03-31 2015-07-09 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI556840B (zh) 2010-11-19 2016-11-11 吉李德科學股份有限公司 治療用組成物
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
AU2013340559B2 (en) 2012-10-29 2018-03-15 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN102911167B (zh) * 2012-11-09 2014-06-25 合肥工业大学 一种高光学纯度的核苷类中间体的制备方法
CN104059057A (zh) * 2014-01-03 2014-09-24 石家庄龙泽制药有限公司 拉米夫定杂质3-tu的制备方法
CN108285895B (zh) * 2018-01-26 2020-06-23 中国科学院南海海洋研究所 一种酯酶EstC11及其编码基因和应用
KR102069443B1 (ko) 2018-08-31 2020-01-22 (주)대한뷰티산업진흥원 울금, 비트 및 무 추출물을 포함하는 바이오셀룰로오스 및 이의 제조방법
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2022011554A1 (zh) * 2020-07-14 2022-01-20 四川大学 3-去氧-2-酮糖酸含氮衍生物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
ATE143016T1 (de) * 1990-11-13 1996-10-15 Iaf Biochem Int Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
AU662130B2 (en) 1991-03-06 1995-08-24 Emory University Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B

Also Published As

Publication number Publication date
ATE469147T1 (de) 2010-06-15
MY114350A (en) 2002-10-31
RO119365B1 (ro) 2004-08-30
CZ295074B6 (cs) 2005-05-18
CA2104399A1 (en) 1992-08-23
PT100151B (pt) 1999-09-30
DK1439177T3 (da) 2010-08-02
IE920545A1 (en) 1992-08-26
CN1127301A (zh) 1996-07-24
NO2005015I1 (no) 2005-07-11
NZ241625A (en) 1996-03-26
CN100396785C (zh) 2008-06-25
WO1992014743A3 (en) 1992-10-29
MX9200747A (es) 1992-09-01
CN1065065A (zh) 1992-10-07
HU9302377D0 (en) 1993-11-29
HU227823B1 (en) 2012-03-28
NO312399B1 (no) 2002-05-06
AU1561792A (en) 1992-09-15
AU679649B2 (en) 1997-07-03
FI20030932A (fi) 2003-06-24
AU665187B2 (en) 1995-12-21
HU211344A9 (en) 1995-11-28
RO122814B1 (ro) 2010-02-26
JPH06508605A (ja) 1994-09-29
HUT65548A (en) 1994-06-28
NO932980L (no) 1993-08-20
WO1992014743A2 (en) 1992-09-03
JP3292830B2 (ja) 2002-06-17
BR9205661A (pt) 1994-05-24
ES2224547T3 (es) 2005-03-01
CN1418966A (zh) 2003-05-21
AU8077398A (en) 1998-10-15
CA2104399C (en) 2005-10-18
NZ250842A (en) 1996-03-26
DE69233379T2 (de) 2005-07-14
CN1037682C (zh) 1998-03-11
IL100965A0 (en) 1992-11-15
FI114915B (fi) 2005-01-31
PT100151A (pt) 1993-05-31
EP0984013B1 (de) 2004-06-30
NO2008010I1 (no) 2008-07-07
KR0172590B1 (ko) 1999-02-01
ES2345102T3 (es) 2010-09-15
CA2513440C (en) 2010-11-30
NO932980D0 (no) 1993-08-20
CN1084745C (zh) 2002-05-15
CN1109108C (zh) 2003-05-21
CZ49792A3 (en) 1993-03-17
EP1439177B1 (de) 2010-05-26
IL100965A (en) 1999-12-31
BG62053B1 (bg) 1999-01-29
EP0984013A2 (de) 2000-03-08
BG98062A (bg) 1994-04-29
ATE270291T1 (de) 2004-07-15
HK1026419A1 (en) 2000-12-15
CN1203232A (zh) 1998-12-30
AU3794395A (en) 1996-03-14
FI933684A0 (fi) 1993-08-20
EP0575482A1 (de) 1993-12-29
CA2513440A1 (en) 1992-09-03
EP0984013A3 (de) 2000-08-02
FI933684A (fi) 1993-09-06
DK0984013T3 (da) 2004-10-25
NO2005015I2 (no) 2007-10-01
JPH10147586A (ja) 1998-06-02
EP1439177A1 (de) 2004-07-21
JP2901160B2 (ja) 1999-06-07
DE69233786D1 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
DE69233379D1 (de) Antivirus Wirkung und Auflösung von 2-Hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
YU74992A (sh) Postupak za pravljenje (-)4-amino-5-fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
TW366346B (en) 1,3-oxathiolane nucleoside analogue
DK0574487T3 (da) Anvendelse af 5-fluor-2'-deoxy-thiacytidin til behandling af hepatitis B
ATE138065T1 (de) Substituierte 1,3-oxathiolane mit antiviraler wirkung
MX9202374A (es) 1,3-oxatiolanos utiles en el tratamiento de hepatitis.
DE69535476D1 (de) Substituierte 1,3-Oxathiolane mit antviralen Eigenschaften
BR9206272A (pt) Derivados de 2-(4-hidroxipiperidino)-1-alcanol, como agentes anti-isquêmicos.
ATE303154T1 (de) Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv
ITMI931582A1 (it) Derivati del 2, 2, 6, 6-tetrametil-4-piperidinolo utili come stabilizzanti alla luce ed all'ossidazione per materiali organici.
RU93058540A (ru) Производные 2-гидроксиметил-5-/5-фторцитозин-1-ил/-1,3-оксатиолан, фармкомпозиция, способы его получения, применение, способы лечения
DK0952157T3 (da) 9a, 11b-dehydroderivater af 9-oxim-3-keto-6-0-methylerythromycin
ATE100318T1 (de) Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition